You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In a separate study, researchers studying the use of Oncotype DX in African-American men found it to be predictive of disease outcomes regardless of race.
The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.
Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.
Research presented at the Intelligent Systems for Molecular Biology conference shows promise in uncovering more SNP-phenotype links in GWAS.
PavMed subsidiary Lucid will commercialize Case Western's EsoCheck technology to detect Barrett's esophagus, a precursor to esophageal cancer.
PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.
In PLOS this week: cancer predisposition among Cowden/Cowden-like and Bannayan-Riley-Ruvalcaba syndrome patients, and more.
In PNAS this week: computational approach combining cancer survival models and machine learning, auxin herbicide resistance mutation, and more.
Working with Case Western Reserve University, the firm will sequence fecal samples from individuals diagnosed with autism and provide results for free to the research community.
The five-year award will provide funding for researchers to investigate genetic determinants of Barrett's Esophagus and esophageal adenocarcinoma.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.